Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a RD day event. Upcoming R.
2
Under new CEO Sanofi stops diabetes heart research and plans 22B in cost cutting Published Dec.
Btki 168 sanofi. Sanofi hosted on April 23 2020 a live webcast and conference call on the detailed Phase 2b results of the investigational BTK inhibitor 168 in relapsing multiple sclerosis. The five-part webcast series was initiated with the presentation of the Phase 2 results and Sanofis development strategy for its brain-penetrant BTKi168 for. Sanofis acquisition of Principia Biopharma would help strengthen the French drugmakers growth under new Chief Executive Officer Paul Hudson.
Initial session focused on brain-penetrant BTKi 168 Phase 2 data Virtual RD day event on June 23 to showcase Sanofis industry leading platforms unique capabilities and innovative medicines to. Estimated regulatory submission timing has not been reviewed by any regulatory authority. BTKi 168 multiple sclerosis.
If positive could trigger 4 Phase 3 trials. The BTKi 168 target profile is aspirational and comparisons with other therapies cannot be made at this time. Virtual RD day event on June 23 to showcase Sanofis industry leading platforms unique capabilities and innovative medicines to.
Upcoming RD sessions on oncology Dupixent dupilumab and nirsevimab Initial session focused on brain-penetrant BTKi 168 Phase 2 data Virtual RD. BTKi 168 aims to address all 5 treatment dimensions with dual mechanism of action Platform injectables Platform orals Natalizumab Alemtuzumab Anti-CD20 BTKi 168 target profile Safety Low treatment burden RR reduction vs. SAR442168 is an investigational oral brain-penetrant selective small-molecule inhibitor of BTK.
The five-part webcast series was initiated with the presentation of the Phase 2 results and Sanofis development strategy for its brain-penetrant BTKi168 for. Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a RD day event Upcoming RD sessions on oncology Dupixent dupilumab and. The efficacy and safety of SA442168 has.
The five-part webcast series was initiated with the presentation of the Phase 2 results and Sanofis development strategy for its brain-penetrant BTKi168 for. Initial session focused on brain-penetrant BTKi 168 Phase 2 data. IR Conference Call on Phase 2b BTKi 168 Trial Results.
The five-part webcast series was initiated with the presentation of the Phase 2 results and Sanofis development strategy for its brain-penetrant BTKi168 for. 10 2019 Andrew Dunn. BTKi SAR442168 is an asset under investigation in collaboration with Principia not approved by regulators.
The final medicine on the list is BTKi 168 described by Sanofi as an oral medicine for multiple sclerosis with potential to be the first disease-modifying therapy to address inflammation and. Expected proof-of-concept readout in first quarter of 2020. SAR442168 has shown BTK binding as well as cerebrospinal fluid exposure in Phase 1 studies.
No head to head studies have been conducted comparing BTKi 168 with any other therapy. BTKi 168 Oncology Dupixent RD Investor Event Nirsevimab Today Synthorx Venglustat Fitusiran BIVV001 COVID-19 Next chapter for Sanofi RD Priority assets SERD 859 Sarclisa Anti-CEACAM5 701 Libtayo. Sanofi buys Synthorx for 25B in prelude to Hudsons strategy rollout.
The company also announced plans to acquire Synthorx Inc which will bolster its immuno-oncology IO pipeline with both a proprietary IO platform synergistic with Sanofis existing therapeutics. BTKi 1685 is an oral medicine for multiple sclerosis with potential to be the first disease-modifying therapy to address inflammation and disability drivers in the brain. BTKi 168 is an oral medicine for multiple sclerosis with potential to be the first disease-modifying therapy to address inflammation and disability drivers in the brain.
2
Sy Investing On Twitter Prnb Sny Sanofi Announced That Sar442168 Brain Penetrant Btki Met The Primary Endpoint Of Its Ph 2 Trial In Relapsing Multiplesclerosis Note That Actual Data Still Needs To Be
Sy Investing On Twitter Prnb Sny Sanofi Announced That Sar442168 Brain Penetrant Btki Met The Primary Endpoint Of Its Ph 2 Trial In Relapsing Multiplesclerosis Note That Actual Data Still Needs To Be